Natera stock: Long-term cancer testing plan remains in focus
Published on 11/19/2026 at 16:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth plan and market move
- Natera's long-term revenue framework centers on Signatera pricing, reimbursement progress and expanding oncology testing.
- Management presented the 2029 target as achievable with strong execution while acknowledging competition and pricing pressure.
- The stock traded materially above the price in the November 17 publication.
Natera stock traded at 275.65 euros on Lang & Schwarz at 16:06 CET on Thursday, November 19, 2026. That was 8.20 percent above the 254.75-euro price cited in our November 17 publication, marking a material change in the share price between the two reports.
Signatera leads the expansion plan
At the Wolfe Research Healthcare Conference on November 10, Natera management set out a long-term revenue target of 6 billion US dollars for 2029. A Reuters report published by Investing.com said the plan depends heavily on Signatera, Natera's personalized minimal residual disease test.
Chief Financial Officer Mike Brophy said the company sees a path from a current Signatera average selling price of 1,290 US dollars to 1,450 US dollars by 2029. Management also estimated a 20 billion to 40 billion US dollar long-term market opportunity, using cancer incidence, repeat testing and broader adoption as key assumptions.
Reimbursement remains central
Natera said reimbursement expansion is an important part of the growth framework. The company has submitted 11 tumor-specific dossiers to Medicare's MolDx program, with liver cancer already covered and further submissions still in process.
The conference discussion also highlighted additional Medicare Advantage reimbursement, commercial biomarker coverage and prospective outcomes data as potential supports for wider use. At the same time, management acknowledged competition in minimal residual disease testing and colorectal cancer screening.
Leadership change adds execution focus
The November 10 discussion also covered the immediate appointment of Solomon Moshtaghian as chief executive officer. Former CEO Steve Tullis remains available as a consultant, while management characterized the transition as continuity rather than a strategic reset.
For investors, the plan combines a substantial oncology opportunity with execution demands. The main variables are Signatera volume, reimbursement, average selling prices and the company's ability to maintain its clinical and commercial lead as competition develops.
Natera company facts
- Company: Natera, Inc.
- ISIN: US6323071042
- Ticker: NTRA
- Primary exchange: Nasdaq
- Lang & Schwarz price: 275.65 euros at 16:06 CET on November 19, 2026
- Change since November 17 publication: 8.20 percent
For broader US market developments, see Current market reports.
